English
norskBlar i forfatter "Al-Shibli, Khalid"
Viser treff 1-12 av 12
-
CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy
(Journal article; Tidsskriftartikkel; Peer reviewed, 2013) -
CD45RO+ Memory T Lymphocytes – a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer
(Journal article; Tidsskriftartikkel; Peer reviewed, 2015-11)Tumor-infiltrating lymphocytes (TILs) are vital in limiting cancer progression and may supplement the TNM classification. CD45RO+ memory TILs show major prognostic impact in various malignancies but have not been extensively explored in non–small cell lung cancer (NSCLC). In this study, we aimed to evaluate their potential in a NSCLC TNM-Immunoscore. Tissue microarrays were constructed from tumor ... -
Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-10-03)<i>Background</i> - MicroRNAs (miRNAs) are promising biomarkers due to their structural stability and distinct expression profile in various cancers. We wanted to explore the miRNA expression in benign breast tissue and breast cancer subgroups in the Norwegian Women and Cancer study.<p> <p><i>Methods</i> - Specimens and histopathological data from study participants in Northern Norway diagnosed ... -
Disease-specific outcomes of Radical Prostatectomies in Northern Norway; A case for the impact of perineural infiltration and postoperative PSA-doubling time
(Tidsskriftartikkel; Journal article; Peer reviewed, 2014)Background Prostate cancer is the most common male malignancy and a mayor cause of mortality in the western world. The impact of clinicopathological variables on disease related outcomes have mainly been reported from a few large US series, most of them not reporting on perineural infiltration. We therefore wanted to investigate relevant cancer outcomes in patients undergoing radical prostatectomy ... -
Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival
(Journal article; Tidsskriftartikkel; Peer reviewed, 2014) -
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ... -
The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival
(Journal article; Tidsskriftartikkel; Peer reviewed, 2016-04-07)background: Operable non-small cell lung cancer (NSCLC) patients whose tumours have spread to regional or central lymph nodes at the time of diagnosis have dismal prognoses compared with those who have limited disease. The current TNM staging system for NSCLC poorly distinguishes patients with lymph-node metastases who will succumb to, and those who will eventually be cured from, their disease. ... -
Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: Combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival
(Journal article; Tidsskriftartikkel; Peer reviewed, 2015-05-29)Background: The chemokine CXCL16 and its receptor CXCR6 are expressed by a variety of immune cells and have been shown to influence angiogenesis. The expression of CXCR6 and CXCL16 has been examined in numerous human cancers; however no studies have yet investigated their influence on prognosis in non-small cell lung cancer (NSCLC). We aimed to explore their prognostic significance in NSCLC, in ... -
Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival
(Master thesis; Mastergradsoppgave, 2015-10-27)BACKGROUND: The chemokine CXCL16 and its receptor CXCR6 are expressed by a variety of immune cells and have been shown to influence angiogenesis. The expression of CXCR6 and CXCL16 has been examined in numerous human cancers; however no studies have yet investigated their influence on prognosis in non-small cell lung cancer (NSCLC). We aimed to explore their prognostic significance in NSCLC, in ... -
Prognostic Impact of Fibroblast Growth Factor 2 in NSCLC : Co-Expression with VEGFR-3 and PDGF-B Predicts Poor Survival
(Tidsskriftartikkel; Peer reviewed; Journal article, 2009-05)Purpose: Fibroblast growth factor 2 (FGF2; basic fibroblast growth factor, b-FGF) and its main receptor FGFR-1 are important in both hemangiogenesis and lymphangiogenesis. Murine studies have indicated a close interplay between both FGF2 and platelet-derived growth factor –B (PDGF-B) as well as FGF2 and vascular endothelial growth factor -3 (VEGFR-3). This study investigates the prognostic impact ... -
Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas
(Journal article; Tidsskriftartikkel; Peer reviewed, 2012)Purpose The purpose of this study is to clarify the prognostic significance of expression of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas (STS). Optimised treatment of STS requires better identification of high risk patients who will benefit from adjuvant therapy. The prognostic significance of Jab1, p16, p21, p62, Ki67 and Skp2 in STS has not been sufficiently investigated. ... -
The prognostic significance of the innate and adaptive immune systems in non-small cell lung carcinoma
(Doctoral thesis; Doktorgradsavhandling, 2010-05-27)Lungekreft er knyttet til røyking og har den høyeste dødelighet av alle andre krefttyper. Hvert år får ca. 1,3 millioner mennesker av begge kjønn denne sykdommen på verdensbasis og mer enn 1,1 millioner mennesker dør av den. En britisk analyse publisert i forskningsmagasinet Nature, bekreftet at det forskes lite på lungekreft i forhold til andre kreftformer. I analysen sto lungekreft bak 22 prosent ...
